MOH — authorised 20 February 1953
- Marketing authorisation holder: HOSPIRA
- Status: likely_approved
MOH authorised Infuvite Pediatric on 20 February 1953
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 20 February 1953.
HOSPIRA holds the Israeli marketing authorisation.